Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients
Status:
Completed
Trial end date:
2014-07-10
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether erenumab is safe and well tolerated
in healthy adults and migraine patients. As part of the secondary objectives, this study will
be conducted to characterize the pharmacokinetic (PK) profile of erenumab after multiple
subcutaneous (SC) doses in healthy adults and migraine patients, as well as to characterize
the effect of erenumab on the capsaicin induced increase in dermal blood flow after multiple
SC doses in healthy adults and migraine patients.